Bristol-Myers Squibb Co (NYSE:BMY) stock rose 3.56% (As on February 6, 11:35:39 AM UTC-4, Source: Google Finance) after the company posted fourth-quarter earnings and revenue which topped estimates, fueled by solid demand for its cancer immunotherapy treatment and blood thinner Eliquis. Sales of the cancer immunotherapy, Opdivo, surged by 8.6% to $2.69 billion, while Eliquis revenue increased by 8.1% to $3.45 billion. Growth Portfolio revenues of $7.4 billion increased 16%, or 15% Ex-FX. Revenue growth was primarily driven by our immuno-oncology (IO) portfolio, Camzyos, Breyanzi and Reblozyl. Legacy Portfolio revenues of $5.1 billion decreased 15%, or 16% Ex-FX. Demand increased for Eliquis, which was more than offset by expected continued generic impact across the remainder of the Legacy Portfolio as well as the impacts from higher U.S. government channel rebates. On a non-GAAP basis, net income attributable to Bristol Myers Squibb of $2.6 billion, decreased from $3.4 billion.

BMY in the fourth quarter of FY25 has reported the adjusted earnings per share of $1.26, beating the analysts’ estimates for the adjusted earnings per share of $1.10. The company had reported the adjusted revenue growth of 1.3 percent to $12.50 billion in the fourth quarter of FY25, beating the analysts’ estimates for revenue of $12.27 billion. U.S. revenues were $8.6 billion. International revenues were $3.9 billion. On a non-GAAP basis, gross margin decreased from 74.0% to 71.9%, reflecting a change in product mix. Acquired IPRD charges of $1.4 billion increased from $30 million on a GAAP and non-GAAP basis, primarily driven by the acquisition of Orbital Therapeutics in 2025. Licensing income increased from $48 million to $222 million on a GAAP and non-GAAP basis

The pharmaceutical group also unveiled an upbeat outlook for its 2026 fiscal year, guiding for revenue of around $46 billion to $47.5 billion and adjusted per-share income of $6.05 to $6.35. Both metrics exceeded Bloomberg consensus estimates. In a note, analysts at JPMorgan said the rosy forecast was driven by Eliquis. The drug, which is made in partnership with Pfizer, is anticipated to grow 10% to 15% this year. Observers had been fretting that Eliquis sales would slip in 2026, due to price cuts and the drug being on a list of medicines set to be part of Medicare price negotiations under the Inflation Reduction Act. But the lower price of Eliquis is tipped to actually help Bristol Myers avert some federal government penalties, as per the news agency.